DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) – Market Insights and Market Forecast-2030’ report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) and market trends in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and United Kingdom).
Some of the key facts of the report1. Non-Hodgkin’s Lymphoma is one of the types of blood cancer that affects lymphocytes.2. Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL that accounts for about 22% of newly diagnosed cases of B-cell NHL in the United States.3. B-cell lymphomas consist of around 85% of all NHL cases that are diagnosed in the United States.
Key benefits of the report1. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report covers a descriptive overview and comprehensive insight and CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market in the 6 MM (the United States, EU5 (Germany, Spain, France, Italy, UK).2. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report provides insights on the current and emerging therapies.3. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report provides a global historical and forecasted market covering drug outreach in 6 MM.4. CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma market.
Request for sample pages
“The Market Size of CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma in the 6MM is estimated to be USD 2796.2 Million in 2030.”
Scope of the Report
Report Highlights:
Table of contents1 Key Insights
2 Executive Summary
3 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Overview at a Glance
4 CAR T-Cell Therapy Background and Overview
5 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
6 Unmet Needs
7 Key Endpoints of Non-Hodgkin’s Lymphoma Treatment
8 Marketed CAR T-Cell Therapies for Non-Hodgkin’s Lymphoma
8.1 List of Marketed Products in the 6MM
8.2 KYMRIAH: NOVARTIS
8.3 YESCARTA: Kite Pharma (Gilead Sciences)
9 Emerging CAR T-Cell Therapies for Non-Hodgkin’s Lymphoma
9.1.1 KTE-X19 : Gilead Sciences
9.1.2 JCAR017: Celgene Corporation (a BMS company)
10 CAR T-Cell Therapy for NHL: Six Major Market Analysis
11 Attribute analysis
12 6MM: Market Outlook12.2 EU-5 Market Size
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
13 CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Clinical Trials in 6MM
14 KOL Views – CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma
15 Market Drivers
16 Market Barriers
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/